Targeted Therapy for Cutaneous Melanoma: Beyond BRAF...

Davies, Michael A.

doi:10.17294/2330-0698.1006

Journal of Patient-Centered Research and Reviews

2014

DOI: 10.17294/2330-0698.1006

|View full text |Cite

Targeted Therapy for Cutaneous Melanoma: Beyond BRAF...

Michael A. Davies¹

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2014

2016

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(1 citation statement)

References 80 publications

(105 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Anderson Cancer Center, looks at "Targeted Therapy for Cutaneous Melanoma: Beyond BRAF…" He discusses new molecular targets and the potential of melanoma treatment personalization. 10 Vemurafenib is an oral medication, taken twice daily, that inhibits the mutant form of the BRAF protein (V600E) that is present in approximately 50% of cutaneous melanomas. Vemurafenib is only effective in patients who have the mutation and it may make tumors grow faster if it is given to a patient who does not have it.…”

mentioning

confidence: 99%

Melanoma: Attacking on Many Fronts

Thompson¹

2014

Journal of Patient-Centered Research and Reviews

View full text Add to dashboard Cite

Follow this and additional works at: https://aurora.org/jpcrr Part of the Oncology CommonsJournal of Patient-Centered Research and Reviews ( JPCRR) is a peerreviewed scientific journal whose mission is to communicate clinical and bench research findings, with the goal of improving the quality of human health, the care of the individual patient, and the care of populations. Recommended CitationThompson MA. Melanoma: attacking on many fronts.

show abstract

mentioning

confidence: 99%

Melanoma: Attacking on Many Fronts

Thompson¹

2014

Journal of Patient-Centered Research and Reviews

View full text Add to dashboard Cite

show abstract

Patient-derived tumor xenograft models for melanoma drug discovery

Harris

Joseph

Copland

2016

Expert Opinion on Drug Discovery

View full text Add to dashboard Cite

There is a strong necessity to reassess current approaches in which preclinical experiments are designed and executed in order to minimize unwarranted clinical trials. With rigorously performed preclinical studies, PDTX models have the capability to effectively confirm or deny drug effective outcomes. The ability to do this, however, will demand better aids to guide experimental design, the redefining of preclinical efficacy, and the understanding that these models should be viewed as complementary to other drug prediction and efficacy tools.

show abstract

Cell cycle control as a promising target in melanoma

Lee

Sandhu

McArthur

2015

Current Opinion in Oncology

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Targeted Therapy for Cutaneous Melanoma: Beyond BRAF...

Cited by 3 publications

References 80 publications

Melanoma: Attacking on Many Fronts

Melanoma: Attacking on Many Fronts

Patient-derived tumor xenograft models for melanoma drug discovery

Cell cycle control as a promising target in melanoma

Contact Info

Product

Resources

About